Proteins and Peptides

09 Dec 2018 Generon Presented Positive Phase III Results From a Double-Blind, Placebo Controlled-Clinical Trial of F-627 in Women with Breast Cancer Receiving Myelotoxic Chemotherapy
05 Dec 2018 CERENIS Announces the Results of TANGO, a Phase III Clinical Study Evaluating CER-001 in Patients with HDL Deficiency
04 Dec 2018 Revance’s RT002 Demonstrates Unprecedented Efficacy and Duration In Largest-Ever Aesthetic Neuromodulator Clinical Program
04 Dec 2018 Biotest AG takes next step in developing a new haemophilia therapeutic to target patient needs
03 Dec 2018 Biosimilar Pegfilgrastim Co-Developed by Biocon Receives Approval in EU
29 Nov 2018 Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP
28 Nov 2018 Constant Pharmaceuticals to Initiate Clinical Development of TXA127 for Epidermolysis Bullosa (EB)
28 Nov 2018 Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
28 Nov 2018 PhaseBio Announces Dosing of First Patient in Phase 2b Clinical Trial of PB1046 in Pulmonary Arterial Hypertension
28 Nov 2018 Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers
28 Nov 2018 Bayer receives EU approval for its hemophilia A treatment Jivi®
27 Nov 2018 Octapharma receives Swissmedic approval for fibryga® to treat congenital and acquired fibrinogen deficiencies
27 Nov 2018 Sandoz receives eighth European Commission approval for a biosimilar with Ziextenzo® (pegfilgrastim)
26 Nov 2018 Immune Regulation Announces Positive Results from Phase 1 Clinical Trial of PIN201104
24 Nov 2018 European Commission Approves Pelmeg▼® (pegfilgrastim) as a Biosimilar Treatment to Reduce the Duration of Neutropenia and Incidence of Febrile Neutropenia in Adults Treated with Chemotherapy
23 Nov 2018 Oral semaglutide demonstrates favourable cardiovascular safety profile and significant reduction in cardiovascular death and all-cause mortality in people with type 2 diabetes in the PIONEER 6 trial
11 Nov 2018 Brooklyn ImmunoTherapeutics Announces Presentation of Positive Results of IRX-2 Therapy in Resectable Breast Cancer and Head and Neck Cancer at the 33rd Annual Meeting of the Society for Immunotherapy of Cancer
09 Nov 2018 Codexis Announces Results of Phase 1a Clinical Trial with CDX-6114
07 Nov 2018 Cancer Targeted Technology Files Investigational New Drug Application for CTT1403, a Novel Radiotherapeutic Drug for Prostate Cancer
07 Nov 2018 New Clinical Oncology Collaboration Between Nektar and Pfizer to Evaluate Combination of NKTR-214, a CD122-Biased Agonist, with Avelumab and Talazoparib or Enzalutamide in Multiple Cancers
07 Nov 2018 Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
07 Nov 2018 Endo Announces Positive Results from Phase 3 Studies of Collagenase Clostridium Histolyticum (CCH) in Patients with Cellulite
03 Nov 2018 U.S. FDA Approves UDENYCA™ (pegfilgrastim-cbqv)
29 Oct 2018 Abicipar Phase 3 Data Presented at AAO Conference in Chicago: Potential to be the First Fixed 12-week Anti-VEGF Therapeutic
28 Oct 2018 Oral semaglutide demonstrates statistically significant reductions in HbA1c and body weight in people with long duration of type 2 diabetes treated with insulin

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2018 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up